HS

Harcharan Singh

Active Director Director DIN 02852915
DIN 02852915 First appointment Dec 2009 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Dec 2009
Shareholding value •••• Premium profile

About Harcharan Singh

Data last updated:

Harcharan Singh is a Director at Biophore India Pharmaceuticals Private Limited (since 2015), Designated Partner at Leiutis Pharmaceuticals Llp (since 2021) and Director at Glopec International (India) Private Limited (since 2010). The companies operate in Pharma and Chemicals. The 3 current companies with reported revenue have a combined latest revenue of ₹509 Cr; the largest is Biophore India Pharmaceuticals Private Limited at ₹457 Cr (FY 2025). Earlier, Harcharan Singh was a Nominee Director at Ra Chem Pharma Limited (2012–2017) and Director at Concord Biotech Limited (2009–2016).

DIN 02852915
Primary Designation Director
Industry Pharma
First Appointment 04 Dec 2009
Oldest Company Age 19 yrs
Largest company Biophore India Pharmaceuticals Private Limited · ₹457 Cr (FY 2025)
Combined revenue ₹509 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Jul 20152007₹457 Cr (FY 2025)Active
Designated Partner17 May 20212021₹52.13 Cr (FY 2025)Active
Director22 Nov 20102010₹12 Lakh (FY 2025)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ra Chem Pharma Limited U24110TG1996PLC022816
Nominee Director15 Feb 20121996₹621 Cr (FY 2021)Amalgamated
Concord Biotech Limited L24230GJ1984PLC007440
Director04 Dec 20091984₹888 Cr (FY 2023)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Leiutis Pharmaceuticals Llp
Biophore India Pharmaceuticals Private Limited
Glopec International (India) Private Limited
Ra Chem Pharma Limited
Premium access

Shareholding and investment profile for Harcharan Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Harcharan Singh

Harcharan Singh currently holds 3 directorships: Biophore India Pharmaceuticals Private Limited (Director, since 10 Jul 2015, revenue ₹457 Cr (FY 2025)); Leiutis Pharmaceuticals Llp (Designated Partner, since 17 May 2021, revenue ₹52.13 Cr (FY 2025)); Glopec International (India) Private Limited (Director, since 22 Nov 2010, revenue ₹12 Lakh (FY 2025)).

Harcharan Singh was first appointed on 04 Dec 2009 as Director at Concord Biotech Limited. The most recent appointment on record is 17 May 2021 at Leiutis Pharmaceuticals Llp.

The 3 current companies of Harcharan Singh that report revenue have a combined latest revenue of ₹509 Cr: Biophore India Pharmaceuticals Private Limited ₹457 Cr (FY 2025); Leiutis Pharmaceuticals Llp ₹52.13 Cr (FY 2025); Glopec International (India) Private Limited ₹12 Lakh (FY 2025).

Harcharan Singh held 2 earlier board appointments: Ra Chem Pharma Limited (Nominee Director, 15 Feb 2012 to 04 Jan 2017); Concord Biotech Limited (Director, 04 Dec 2009 to 05 Jul 2016).

The current boards of Harcharan Singh's companies include Jagadeesh Babu Rangisetty (Biophore India Pharmaceuticals Private Limited), Madhusudana Rao Kothapalli (Biophore India Pharmaceuticals Private Limited), Manikreddy Pullagurla (Biophore India Pharmaceuticals Private Limited), Chandra Shekhar Kocherlakota (Leiutis Pharmaceuticals Llp), Ramprasad Nimmagadda (Leiutis Pharmaceuticals Llp), Kashyap Suresh Shah (Glopec International (India) Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available